Clinical trials: Low Cardiovascular Risk
Aortic Valve Stenosis
Randomized Trial of TAVI vs. SAVR in Patients With Severe Aortic Valve Stenosis at Low to Intermediate Risk of Mortality
Randomized controlled, multi-center trial randomizing patients with symptomatic severe aortic stenosis at low to intermediate operative risk of mortality in a 1:1 fashion to transcatheter aortic valve implantation (TAVI) or…
- Trial name
- DEDICATE (NCT03112980)
- Testing
- Transcatheter aortic valve implantation, Surgical aortic valve replacement
- Where
- 43 sites in Germany
- Volunteers
- 1,414 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Chest Pain
Risk Evaluation and Stratification of Low Risk for Cardiovascular Disease in Women
This study will evaluate the ability of Coronary Computed Tomography Angiography (CCTA), used as a first-line diagnostic tool in women with stable chest pain and low risk for Coronary Artery Disease (CAD), to reduce the number of…
- Trial name
- RESOLVE (NCT03929341)
- Testing
- Coronary Computed Tomography Angiography (CCTA), Cardiac Link
- Where
- Canada
- Volunteers
- 130 people
- Sponsor
- Elsie Nguyen
Peripheral Arterial Disease, Atherosclerosis of Extremities
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
The Low dose ColchicinE in pAtients with peripheral Artery DiseasE to address residual vascular Risk (LEADER-PAD) trial will evaluate if anti-inflammatory therapy with colchicine will reduce vascular events in patients with…
- Conditions
- Peripheral Arterial Disease, Atherosclerosis of Extremities, Inflammation
- Trial name
- LEADER-PAD (NCT04774159)
- Testing
- Colchicine 0.5 MG Oral Tablet
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 6,150 people
- Sponsor
- Population Health Research Institute
Cardiovascular Disease
Same Day Versus Next Day Discharge: Ambulatory Closure Device Percutaneous Intervention
This is a multi-center trial that will evaluate the safety, feasibility, and cost effectiveness of discharging patients, who have had successful percutaneous coronary intervention (PCI) and deployment of the AngiomaxTM closure…
- Trial name
- ABCD-PCI (NCT01230606)
- Testing
- discharge vs. overnight stay
- Where
- 2 sites in United States
- Volunteers
- 303 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Sars-CoV2, COVID
Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients
The aim of this study is to test the hypothesis that prophylaxis of severe COVID-19 patients with treatment dose LMWH leads to better thromboembolic-free outcomes and associated complications during hospitalization than…
- Trial name
- NCT04401293
- Testing
- Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin
- Where
- 6 sites in United States
- Volunteers
- 257 people
- Sponsor
- Northwell Health
Cystic Fibrosis, Endothelial Dysfunction
Vascular Health and Function in Cystic Fibrosis
The goal of this observational study is to learn whether blood vessel health and function differ between adults aged 40 years or older with cystic fibrosis (CF) who are taking CFTR modulator therapy and healthy adults of the same…
- Conditions
- Cystic Fibrosis, Endothelial Dysfunction, Cardiovascular Risk Factor
- Trial name
- CF-VHF (NCT07904325)
- Testing
- Non-invasive vascular, cerebrovascular and autonomic assessment
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Liverpool Heart and Chest Hospital NHS Foundation Trust
Fibrillation, Atrial, Atrial Fibrillation
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
This study will allow determination of the pharmacokinetic and pharmacodynamics of SB424323 in a relevant population. The data from this study will be used along with other data to aid in choosing the most appropriate dose for…
- Trial name
- NCT00240643
- Testing
- SB424323
- Where
- 116 sites in United States, Argentina and 23 more
- Volunteers
- 640 people
- Sponsor
- GlaxoSmithKline
Venous Thromboembolism, Bleeding as Surgical Complication (Treatment)
Enoxaparin Versus Placebo for Venous Thromboembolism Prevention in Low Risk Cancer Patients After Surgical Procedures: a Randomized, Double Blind, Placebo Controlled Clinical Trial Pilot Study
Post-surgical bleeding is a major source of morbidity in cancer patients, and ramifications can include need for transfusion, increased length of hospital stay, unexpected return to the operating room, or even death.
- Conditions
- Venous Thromboembolism, Bleeding as Surgical Complication (Treatment), Deep Venous Thrombosis, Pulmonary Embolism
- Trial name
- NCT03988231
- Testing
- Receipt of enoxaparin
- Sponsor
- University of Utah
Low Risk Acute Coronary Syndrome
Low Risk Acute Coronary Syndrome
A large number of patients are diagnosed with low risk ACS, and these individuals are at significant cardiovascular risk. Though guidelines recommend stress testing to manage low risk ACS patients, evidence supporting this…
- Trial name
- LOW ACT (NCT01703156)
- Testing
- Stress Test, No Stress Test
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Oklahoma
Venous Thromboembolism, Venous Thrombosis
Intermittent Pneumatic Compression in Surgical Patients at Extremely-high Risk for Venous Thromboembolism
The aim of the study is to evaluate efficacy and safety of venous thromboembolism prophylaxis by the combination of graduated compression stockings (GCS), standard doses of low-molecular-weight heparins (LMWH) and sequential…
- Trial name
- IPCSUPER (NCT03044574)
- Testing
- SCD, GCS, LMWH
- Where
- 2 sites in Russia
- Volunteers
- 407 people
- Sponsor
- Pirogov Russian National Research Medical University
Hypercholesterolemia
Nutraceutical in Cardiovascular Primary Prevention
Nutraceuticals have attracted interest as possible approach to be associated with lifestyle changes for lowering plasma cholesterol levels in patients with moderate hypercholesterolemia.
- Trial name
- NIRVANA (NCT03216811)
- Testing
- nutraceutical
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- University Hospital of Ferrara
Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk
The primary objective of the study was to evaluate the effect of 12 weeks of subcutaneous evolocumab administered every 2 weeks and once a month, compared with placebo, on percent change from baseline in LDL-C when used in…
- Trial name
- AMG145 (NCT01953328)
- Testing
- Atorvastatin, Evolocumab
- Where
- 54 sites in Japan
- Volunteers
- 409 people
- Sponsor
- Amgen
Rare Diseases, Marfan Syndrome
Analysis of Muscular Properties in Patients With MFS and EDS
The goal of this observational study is to learn and assess muscle morphological and electromechanical properties in patients affected with Marfan syndrome (MFS) and Ehlers Danlos syndrome (EDS).
- Conditions
- Rare Diseases, Marfan Syndrome, Ehlers-Danlos Syndrome
- Trial name
- MUSCLE (NCT05720923)
- Testing
- Analysis with Ergometer
- Where
- Italy
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- IRCCS Policlinico S. Donato
Type 2 Diabetes, Heart Diseases
Egg Intake and Risk of Type 2 Diabetes
This is a longitudinal study that will collect demographic, anthropometric and dietary data to determine the relationships between meat and egg intake and the incidence of Type 2 Diabetes.
- Trial name
- ES (NCT03406910)
- Where
- United States
- Volunteers
- 55,851 people, healthy volunteers welcome
- Sponsor
- Loma Linda University
Diabetic Retinopathy
Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy
This multicenter, open-label extension study will evaluate the long-term tolerability and safety for patients completing study CSMS995 0802.
- Trial name
- NCT00248157
- Testing
- Octreotide acetate in microspheres
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Myocardial Infarction, Heart Failure
Personalised Risk scOre For Implantation of Defibrillators in Patients With Reduced LVEF≤35% and a Low Risk for Sudden Cardiac Death
The objective of the study is to demonstrate that in post-MI patients with symptomatic heart failure who receive optimal medical therapy for this condition, and with reduced LVEF ≤ 35% but low risk for SCD according to a…
- Conditions
- Myocardial Infarction, Heart Failure, Sudden Cardiac Death
- Trial name
- PROFID-Reduced (NCT04540354)
- Testing
- Optimal Medical Therapy (OMT), Implantable cardioverter-defibrillator (ICD)
- Sponsor
- Helios Health Institute GmbH
Dyslipidemia
Effect of Compound (Cardiol Forte) on Lipid And Glycemic Parameters in Low Cardiovascular Risk Individuals
This study will evaluate the effects of a combination dietary supplement, Cardiol Forte, on lipid and glycemic parameters in adults at low cardiovascular risk with suboptimal cholesterol levels.
- Trial name
- CLARISKI (NCT07515573)
- Testing
- Cardiol Forte
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- U.G.A. Nutraceuticals
Atherosclerotic Cardiovascular Risk, Low-density-lipoprotein (LDL) Cholesterol
Cardiovascular Risk Categories and Attaining LDL-C Targets in Middle Eastern Adults Aged 30-55 Years of Age
Individuals evaluated for primary and secondary cardiovascular prevention have different levels of cardiovascular risk These levels of risk are the main determinants of the low-density lipoprotein cholesterol (LDL-C) target blood…
- Trial name
- CREATE (NCT05745272)
- Where
- Jordan
- Volunteers
- 1,000 people
- Sponsor
- Jordan Collaborating Cardiology Group
Left Ventricular Dysfunction
IMpella-Protected cArdiaC Surgery Trial (IMPACT)
The purpose of this Trial is to demonstrate the safety and effectiveness of the use of Impella 5.5 in high-risk cardiac surgery patients, with the overall aim to evaluate if using Impella 5.5 with SmartAssist (Impella 5.5)…
- Trial name
- IMPACT (NCT05529654)
- Testing
- Impella 5.5 with SmartAssist
- Where
- 20 sites in United States
- Volunteers
- 100 people
- Sponsor
- Abiomed Inc.
Peptic Ulcer Disease
Study Comparing Esomeprazole and ASA Combined Together as One Capsule Versus These Medications Taken Separately
The purpose of this study is to investigate whether a fixed dose combination (FDC) capsule of esomeprazole 20 mg and acetylsalicylic acid (ASA) 81 mg has equivalent therapeutic efficacy compared to each of 2 free combinations of…
- Trial name
- NCT01015729
- Testing
- Esomeprazole/ASA Fixed Combination, Esomeprazole, ASA
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca